Suppliers and packagers for DEXTROSE 25%

DEXTROSE 25%

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	DEXTROSE 25%	dextrose	INJECTABLE;INJECTION	019445	NDA	Henry Schein, Inc.	0404-9844-10	1 SYRINGE in 1 BAG (0404-9844-10) / 10 mL in 1 SYRINGE	2022-01-10
Hospira	DEXTROSE 25%	dextrose	INJECTABLE;INJECTION	019445	NDA	Henry Schein, Inc.	0404-9845-50	1 SYRINGE in 1 BAG (0404-9845-50) / 50 mL in 1 SYRINGE	2022-01-10
Hospira	DEXTROSE 25%	dextrose	INJECTABLE;INJECTION	019445	NDA	Henry Schein, Inc.	0404-9847-50	1 VIAL, SINGLE-DOSE in 1 BAG (0404-9847-50) / 50 mL in 1 VIAL, SINGLE-DOSE	2022-01-10

Suppliers and packagers for DEXTROSE 25%

Last updated: May 29, 2026

Suppliers for Dextrose 25% (USP 25% Glucose Injection): Who Manufactures, What They Supply, and Where to Source

Executive summary: Dextrose 25% (25 g/100 mL) is a widely stocked USP “Glucose Injection” strength. Supply is dominated by large IV solution manufacturers and contract packagers that produce sterile, non-PVC or PVC compatible IV containers and distribute through national wholesalers and hospital distributors. When sourcing, buyers typically choose among (1) finished sterile injection manufacturers, (2) contract sterile manufacturers who supply private label, and (3) distributor channels that can bundle stocking, cold-chain logistics (when applicable for other products), and 24/7 fulfillment.

Who supplies Dextrose 25% (25% glucose injection) to hospitals and distributors?

Short answer: Dextrose 25% is supplied by multiple USP-compliant sterile IV solution manufacturers and relabeled/private-label producers, distributed through national pharmaceutical wholesalers and hospital supply networks. The most common product is “Dextrose Injection USP, 25%” packaged as single-dose IV bottles or via pharmacy bulk packaging formats depending on the facility.

What is “Dextrose 25%” in the supply chain?

• Generic drug name: Dextrose Injection USP (Glucose Injection USP)
• Strength: 25% (commonly 25 g/100 mL)
• Dosage form: Sterile injection for IV use
• Packaging: single-dose IV containers are typical; container type may vary by manufacturer (glass vs plastic), and facility compatibility drives selection.

Typical sourcing paths

1. Finished-dose manufacturer supply
   • Buyer purchases the finished sterile injection product under the manufacturer’s label.
2. Private-label/contract sterile supply
   • Buyer or distributor requests a relabeled version made under GMP by a contract sterile line.
3. Distribution-channel procurement
   • Buyer purchases via wholesaler or group purchasing organization (GPO) inventory.

Which companies manufacture Dextrose Injection USP 25% (and comparable glucose IV strengths)?

Short answer: The supplier roster is broad, and manufacturers often also produce other dextrose strengths (D10, D20, D50) and multi-electrolyte IV solutions. Supply continuity usually tracks with sterile IV solution capacity and container availability rather than with dextrose-specific IP.

Manufacturer categories that supply Dextrose 25%

• Large sterile IV solution producers
  • Produce high-volume dextrose injections and related IV therapies.
• Sterile contract manufacturers
  • Provide private-label or distributor-branded sterile IV solutions.
• Relabelers
  • Repackage/relabel finished sterile product for channel partners.

How to interpret supplier listings in practice

• If a wholesaler lists “Dextrose 25% Injection,” the underlying product can map to one or more OEM manufacturers, but the listing is channel-specific.
• Procurement systems (hospital ERP and GPO catalogs) often show:
  • NDC
  • container size
  • manufacturer labeler
  • wholesaler availability
  • alternative NDCs at different container types or strengths.

How can buyers validate the right supplier for Dextrose 25% (USP) using NDCs and specs?

Short answer: Buyers validate supplier fit by locking the NDC, container type, and USP/NF labeling, then confirming sterile manufacturing controls and distribution compliance.

Buyer validation checklist

• NDC matches the desired strength, container size, and labeler.
• Container compatibility aligns with facility policy (for example, infusion set compatibility).
• USP status: “Dextrose Injection USP” (strength-specific).
• Labeling: route of administration and storage requirements.
• Lot traceability: batch number and expiration alignment with receiving window.
• Distribution terms: contract lead times and return/refill policies.

Why NDC-level selection matters

Dextrose 25% is a standardized strength, but suppliers can differ on:

• container type and material
• fill volume and final count of units
• labeler and packaging configuration
• distribution channel and stocking locations

What packaging formats and container types affect supplier availability for Dextrose 25%?

Short answer: Packaging constraints are a primary supply lever for IV dextrose products. Facility preferences on container type and pharmacy workflow (single-dose units vs casepacks) can shift supplier lead times.

Common packaging decisions that change sourcing

• Bottle vs plastic container
• Single-dose vs multipack
• Case size and unit count per shipping carton
• Label configuration for barcode scanning in hospital systems
• Compatibility with infusion protocols

Are there alternative suppliers if Dextrose 25% is backordered?

Short answer: Yes. The fastest substitution typically comes from alternate NDCs that are pharmaceutically equivalent (same strength, USP label) and compatible with the facility’s IV system.

Substitution patterns procurement teams use

• Same strength, alternate container type
• Same therapeutic function, alternate dextrose strength for protocol-driven titration (clinician dependent)
• Alternate distributor inventory, sometimes from different national stocking points

Operational risk controls

• Ensure substitution keeps:
  • same concentration (25%)
  • appropriate container/volume
  • USP labeling
  • infusion compatibility

What regulatory and quality signals matter for Dextrose 25% suppliers?

Short answer: Buyers focus on manufacturer GMP compliance, inspection history signals, product quality reporting, and shortage notifications that can impact delivery.

Regulatory signals procurement teams track

• FDA shortage updates affecting specific NDCs
• Recalls or quality alerts tied to manufacturer sites or product lots
• Inspection outcomes relevant to sterile manufacturing

How those signals translate into supplier choices

• If one labeler’s NDC is flagged repeatedly for shortage/availability, procurement shifts to alternate NDC labelers first.
• If the underlying manufacturing site issues affect multiple NDCs, buyers pivot to different OEM production lines.

How do distribution channels influence which Dextrose 25% supplier you get?

Short answer: The wholesaler or distributor contract determines which labeler NDC you actually receive, even when the hospital formulary lists “Dextrose 25%.”

Key channel mechanics

• GPO contracts: channel-specific pricing and stocking commitments
• Wholesaler allocation during shortages
• Substitution rules in purchasing policies
• Regional distribution centers that affect lead time

Key Takeaways

• Dextrose 25% is a broadly supplied USP sterile IV product, sourced via multiple sterile IV manufacturers and distribution channels.
• Procurement should be NDC-driven: validate strength, container type, and labeler through the hospital ERP or procurement catalog.
• Supplier availability is often constrained by sterile IV container and line capacity, so switching labeler NDCs typically works faster than changing therapeutic concentration or protocol.
• Quality and compliance monitoring should track FDA shortage and quality signals at the NDC and labeler/manufacturer site level.

FAQs

1) What is the NDC-specific way to identify the right Dextrose 25% product?

Match the hospital or distributor NDC to the exact concentration, container size, and labeler; procurement systems should treat NDC as the unit of equivalence.

2) Can I substitute Dextrose 25% with another glucose IV strength?

Protocol and clinical oversight determine interchangeability. Procurement substitution should prioritize the same dextrose strength and USP labeling whenever possible.

3) How do I find the “same product” from another supplier?

Use NDC cross-referencing in your procurement catalog, focusing on “Dextrose Injection USP 25%” and the same container size where required.

4) What drives Dextrose 25% shortages?

Sterile IV manufacturing capacity and packaging/container availability are typical drivers; channel allocation during shortages determines which labelers remain available.

5) What documentation should suppliers provide for sterile dextrose injections?

Expect batch/lot traceability, COA where applicable, expiration and storage conditions per labeling, and distribution compliance terms tied to your purchasing agreement.

References

1. U.S. Food and Drug Administration. (n.d.). FDA Drug Shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
2. U.S. Food and Drug Administration. (n.d.). Drug recall information. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/recalls
3. U.S. National Library of Medicine. (n.d.). DailyMed. https://dailymed.nlm.nih.gov/dailymed/